Literature DB >> 33740454

Novel approaches for vaccine development.

Makda S Gebre1, Luis A Brito2, Lisa H Tostanoski3, Darin K Edwards2, Andrea Carfi4, Dan H Barouch5.   

Abstract

Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, complex viral antigens, and emerging pathogens. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well-suited to address existing technology limitations. In this review, we discuss the current state of RNA vaccines, recombinant adenovirus vector-based vaccines, and advances from biomaterials and engineering that address these important public health challenges.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33740454      PMCID: PMC8049514          DOI: 10.1016/j.cell.2021.02.030

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  145 in total

1.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.

Authors:  Katalin Karikó; Michael Buckstein; Houping Ni; Drew Weissman
Journal:  Immunity       Date:  2005-08       Impact factor: 31.745

2.  Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

Authors:  Akin Akinc; William Querbes; Soma De; June Qin; Maria Frank-Kamenetsky; K Narayanannair Jayaprakash; Muthusamy Jayaraman; Kallanthottathil G Rajeev; William L Cantley; J Robert Dorkin; James S Butler; Liuliang Qin; Timothy Racie; Andrew Sprague; Eugenio Fava; Anja Zeigerer; Michael J Hope; Marino Zerial; Dinah W Y Sah; Kevin Fitzgerald; Mark A Tracy; Muthiah Manoharan; Victor Koteliansky; Antonin de Fougerolles; Martin A Maier
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

3.  Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.

Authors:  Peter Abbink; Angelique A C Lemckert; Bonnie A Ewald; Diana M Lynch; Matthew Denholtz; Shirley Smits; Lennart Holterman; Irma Damen; Ronald Vogels; Anna R Thorner; Kara L O'Brien; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

Review 4.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

5.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

Authors:  M A Rosenfeld; K Yoshimura; B C Trapnell; K Yoneyama; E R Rosenthal; W Dalemans; M Fukayama; J Bargon; L E Stier; L Stratford-Perricaudet
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

6.  Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

Authors:  Shinu John; Olga Yuzhakov; Angela Woods; Jessica Deterling; Kimberly Hassett; Christine A Shaw; Giuseppe Ciaramella
Journal:  Vaccine       Date:  2018-02-15       Impact factor: 3.641

7.  Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Authors:  Dan H Barouch; Frank L Tomaka; Frank Wegmann; Daniel J Stieh; Galit Alter; Merlin L Robb; Nelson L Michael; Lauren Peter; Joseph P Nkolola; Erica N Borducchi; Abishek Chandrashekar; David Jetton; Kathryn E Stephenson; Wenjun Li; Bette Korber; Georgia D Tomaras; David C Montefiori; Glenda Gray; Nicole Frahm; M Juliana McElrath; Lindsey Baden; Jennifer Johnson; Julia Hutter; Edith Swann; Etienne Karita; Hannah Kibuuka; Juliet Mpendo; Nigel Garrett; Kathy Mngadi; Kundai Chinyenze; Frances Priddy; Erica Lazarus; Fatima Laher; Sorachai Nitayapan; Punnee Pitisuttithum; Stephan Bart; Thomas Campbell; Robert Feldman; Gregg Lucksinger; Caroline Borremans; Katleen Callewaert; Raphaele Roten; Jerald Sadoff; Lorenz Scheppler; Mo Weijtens; Karin Feddes-de Boer; Daniëlle van Manen; Jessica Vreugdenhil; Roland Zahn; Ludo Lavreys; Steven Nijs; Jeroen Tolboom; Jenny Hendriks; Zelda Euler; Maria G Pau; Hanneke Schuitemaker
Journal:  Lancet       Date:  2018-07-06       Impact factor: 79.321

Review 8.  Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.

Authors:  Lampouguin Yenkoidiok-Douti; Christopher M Jewell
Journal:  ACS Biomater Sci Eng       Date:  2020-01-12

Review 9.  Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health.

Authors:  Chelsea N Fries; Elizabeth J Curvino; Jui-Lin Chen; Sallie R Permar; Genevieve G Fouda; Joel H Collier
Journal:  Nat Nanotechnol       Date:  2020-08-17       Impact factor: 39.213

Review 10.  The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology.

Authors:  Apolonia Luis
Journal:  Viruses       Date:  2020-09-29       Impact factor: 5.048

View more
  37 in total

Review 1.  Breast cancer vaccines for treatment and prevention.

Authors:  Mary L Disis; Denise L Cecil
Journal:  Breast Cancer Res Treat       Date:  2021-11-30       Impact factor: 4.872

Review 2.  Biomimetic Exosomes: A New Generation of Drug Delivery System.

Authors:  Xudong Wang; Xian Zhao; Youxiu Zhong; Jiuheng Shen; Wenlin An
Journal:  Front Bioeng Biotechnol       Date:  2022-05-23

3.  A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).

Authors:  Brett Leav; Walter Straus; Phil White; Alison Leav; Tashawnee Gaines; Grace Maggiacomo; Denny Kim; Emily R Smith; Marc Gurwith; Robert T Chen
Journal:  Vaccine       Date:  2022-06-09       Impact factor: 4.169

Review 4.  Advances in mRNA vaccines.

Authors:  Mengyun Li; Zining Wang; Chunyuan Xie; Xiaojun Xia
Journal:  Int Rev Cell Mol Biol       Date:  2022-06-21       Impact factor: 6.420

Review 5.  COVID-19 Vaccines: Adenoviral Vectors.

Authors:  Catherine Jacob-Dolan; Dan H Barouch
Journal:  Annu Rev Med       Date:  2021-10-05       Impact factor: 13.739

Review 6.  Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines.

Authors:  Heedo Park; Mee Sook Park; Jong Hyeon Seok; Jaehwan You; Jineui Kim; Jeonghun Kim; Man-Seong Park
Journal:  J Microbiol       Date:  2022-03-02       Impact factor: 2.902

Review 7.  Lipid nanoparticles for mRNA delivery.

Authors:  Xucheng Hou; Tal Zaks; Robert Langer; Yizhou Dong
Journal:  Nat Rev Mater       Date:  2021-08-10       Impact factor: 66.308

8.  Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.

Authors:  Daniel Ellis; Natalie Brunette; Katharine H D Crawford; Alexandra C Walls; Minh N Pham; Chengbo Chen; Karla-Luise Herpoldt; Brooke Fiala; Michael Murphy; Deleah Pettie; John C Kraft; Keara D Malone; Mary Jane Navarro; Cassandra Ogohara; Elizabeth Kepl; Rashmi Ravichandran; Claire Sydeman; Maggie Ahlrichs; Max Johnson; Alyssa Blackstone; Lauren Carter; Tyler N Starr; Allison J Greaney; Kelly K Lee; David Veesler; Jesse D Bloom; Neil P King
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

9.  Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.

Authors:  Yongfei Cai; Jun Zhang; Tianshu Xiao; Christy L Lavine; Shaun Rawson; Hanqin Peng; Haisun Zhu; Krishna Anand; Pei Tong; Avneesh Gautam; Shen Lu; Sarah M Sterling; Richard M Walsh; Sophia Rits-Volloch; Jianming Lu; Duane R Wesemann; Wei Yang; Michael S Seaman; Bing Chen
Journal:  Science       Date:  2021-06-24       Impact factor: 63.714

Review 10.  Universally Immune: How Infection Permissive Next Generation Influenza Vaccines May Affect Population Immunity and Viral Spread.

Authors:  Maireid B Bull; Carolyn A Cohen; Nancy H L Leung; Sophie A Valkenburg
Journal:  Viruses       Date:  2021-09-06       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.